YOLT-101 Phase I interim data show 52% LDL reduction in investigator-led trial

YolTech Therapeutics/YOLT-101

Interim Phase I results from an investigator-led trial at Renji Hospital and Shanghai Jiao Tong University demonstrated that YOLT-101 achieved 50% LDL-C reduction and 76% PCSK9 reduction in the highest-dose cohort. The data supported regulatory approvals in both China and the United States.

• Phase I trial enrolled patients with heterozygous familial hypercholesterolemia.
• Highest-dose patients showed 50.4% LDL reduction and 75.8% PCSK9 reduction at 4 months.
• Safety profile favorable with mild infusion-related reactions and temporary liver enzyme elevations.
• First clinical validation of in vivo base editing for cardiovascular disease.